PASSAGE BIO

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that the first patient has been dosed in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations. FTD is a form of early onset dementia with no approved disease-modifying therapies.

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Passage Bio, Inc. (NASDAQ:PASG ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Stuart Henderson - VP of Corporate Development and IR Edgar Cale - Interim CEO Simona King - CFO Mark Forman - Chief Medical Officer Conference Call Participants Brendan Smith - Cowen Neena Bitritto-Garg - Citi Alex Nackenoff - Raymond James Laura Chico - Wedbush Operator Good morning and welcome to the Passage Bio Second Quarter 2022 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.

Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript

PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will participate in a virtual panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Virtual Conference being held from August 9-10, 2022.

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

PHILADELPHIA, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights.

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results and discuss recent business highlights.

Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

PHILADELPHIA, July 06, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of Michael Kamarck, Ph.D., to its board of directors and his appointment to the Nominating and Corporate Governance Committee. Dr. Kamarck is a seasoned biopharmaceutical executive with over forty years of experience in discovery research, process development and technical operations.

Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors

PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Simona King, chief financial officer of Passage Bio, will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference being held from June 13-16, 2022 in Rancho Palos Verdes, CA.

Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

• PBML04 represents the company's fourth program to receive IND clearance

Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced today that the board of directors and Bruce Goldsmith, Ph.D. have mutually agreed that Dr. Goldsmith will step down as president and chief executive officer and a member of the board, effective immediately. The board has appointed Edgar B. (Chip) Cale, the current general counsel and corporate secretary, as interim CEO. Dr. Goldsmith will serve as a strategic advisor to management and the board for a transition period.

Passage Bio Announces Leadership Transition

PHILADELPHIA, May 20, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees.

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the presentation of longer-term clinical and biomarker data from Cohort 1 in Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis (GM1). David Weinstein, M.D. M.M.Sc., senior vice president, Clinical Development, Passage Bio, will present the data at 8:30 a.m. ET during a late-breaker oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Washington, D.C. and virtually.

Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting

Passage Bio, Inc. (NASDAQ:PASG ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Stuart Henderson - Vice President of Corporate Development and Investor Relations Bruce Goldsmith - President and CEO Eliseo Salinas - Chief Research and Development Officer Simona King - Chief Financial Officer Conference Call Participants Madhu Kumar - Goldman Sachs Tessa Romero - JPMorgan Neena Bitritto-Garg - Citi Brendan Smith - Cowen & Company Daniel Brill - Raymond James Operator Thank you for holding. Good morning, and welcome to the Passage Bio First Quarter 2022 Financial and Operating Results Conference Call.

Passage Bio, Inc.'s (PASG) CEO Bruce Goldsmith on Q1 2022 Results - Earnings Call Transcript

PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.

Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 16, 2022, to report its first quarter 2022 financial results and discuss recent business highlights.

Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022

Aware

US crude oil futures traded higher on Friday. Investors, meanwhile, focused on some notable insider trades.

2 Stocks Under $3 Insiders Are Aggressively Buying

PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from Cohort 1 in the Imagine-1 study for GM1 gangliosidosis will be presented at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which is being held in Washington, D.C. and virtually on May 16-19, 2022.

UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from Cohort 1 in the Imagine-1 study for GM1 gangliosidosis will be presented at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which is being held in Washington D.C. and virtually from May 16 to 19, 2022.

Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

PHILADELPHIA, March 15, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today provided an update on strategic priorities to extend its cash runway. The company will decrease operating expenses by reducing the workforce by approximately 13 percent and prioritizing its research and development programs in partnership with the University of Pennsylvania's Gene Therapy Program (GTP). The company will continue to focus on advancing its three lead clinical programs for GM1 gangliosidosis, Krabbe disease and frontotemporal dementia.

Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway

Company expects to report interim safety and biomarker data for Cohort 1 patients in the global phase 1/ 2 clinical trial, GALax-C, by end of 2022 Company expects to report interim safety and biomarker data for Cohort 1 patients in the global phase 1/ 2 clinical trial, GALax-C, by end of 2022

Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

PHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business highlights.

Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights.

Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

PHILADELPHIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today presented updated clinical data from Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis (GM1). The platform presentation at the 18th Annual WORLDSymposium included clinical assessments of development milestones for Cohort 1 (two patients with late infantile GM1 who were administered a low dose of PBGM01). Additionally, the presentation reviewed safety and biomarker data first announced in December 2021.

Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium

PHILADELPHIA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced its participation at the 18th Annual WORLDSymposium, a research conference dedicated to lysosomal diseases, taking place virtually and in person in San Diego, Calif., February 7 – 11, 2022.

Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11

PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Bruce Goldsmith, Ph.D., president, and chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 10:30 a.m. ET.

News for PASSAGE BIO Stock (PASG)